Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Rises By 5.1%

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Based on an average daily volume of 33,700 shares, the days-to-cover ratio is currently 19.1 days. Approximately 10.9% of the shares of the company are short sold.

Insiders Place Their Bets

In other Greenwich LifeSciences news, CEO Snehal Patel bought 3,200 shares of the business's stock in a transaction on Monday, December 30th. The stock was purchased at an average price of $11.12 per share, for a total transaction of $35,584.00. Following the completion of the transaction, the chief executive officer now directly owns 5,539,302 shares of the company's stock, valued at $61,597,038.24. This trade represents a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders acquired 9,500 shares of company stock worth $115,549 over the last quarter. 51.67% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Greenwich LifeSciences

Large investors have recently modified their holdings of the company. State Street Corp boosted its position in shares of Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company's stock valued at $1,026,000 after acquiring an additional 3,005 shares during the period. Geode Capital Management LLC raised its stake in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock valued at $1,919,000 after purchasing an additional 5,861 shares in the last quarter. Barclays PLC raised its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Garden State Investment Advisory Services LLC purchased a new stake in Greenwich LifeSciences in the third quarter valued at approximately $253,000. Finally, Bank of America Corp DE raised its stake in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after purchasing an additional 1,322 shares in the last quarter. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Trading Down 0.7 %

Shares of GLSI stock traded down $0.09 during trading hours on Friday, reaching $11.95. The stock had a trading volume of 21,061 shares, compared to its average volume of 33,878. The stock's fifty day simple moving average is $12.49 and its 200 day simple moving average is $13.40. Greenwich LifeSciences has a 12 month low of $10.52 and a 12 month high of $21.44. The firm has a market capitalization of $157.08 million, a PE ratio of -14.94 and a beta of 1.69.

Analyst Ratings Changes

Separately, HC Wainwright restated a "buy" rating and issued a $38.00 price objective on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.